nach oben

Erschienen in:

01.03.2012 | Original article

Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients

verfasst von: Sebastian Ochsenreither, Alberto Fusi, Anne Geikowski, David Stather, Antonia Busse, Andrea Stroux, Anne Letsch, Ulrich Keilholz

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Clinically effective T-cell responses can be elicited by single peptide vaccination with Wilms' tumor 1 (WT1) epitope 126–134 in patients with acute myeloid leukemia (AML). We recently showed that a predominant T-cell receptor (TCR) β chain was associated with vaccine-induced complete remission in an AML patient (patient 1). In this study, we address the question of whether this predominant clone or the accompanying Vβ11 restriction could be found in other AML patients vaccinated with the same WT1 peptide.

Materials and methods

For assessment of Vβ usage, cytotoxic T lymphocytes (CTLs) from four vaccinated patients were divided into specific and non-specific by epitope-specific enrichment. Vβ families were quantified in both fractions using reverse transcribed quantitative PCR. Vβ11-positive ‘complementary determining region 3’ (CDR3) sequences were amplified from these samples, from bone marrow samples of 17 other vaccination patients, and from peripheral blood of six healthy controls, cloned and sequenced.

Results

We observed a clear bias towards Vβ11 usage of the WT1-specific CTL populations in all four patients. The predominant CDR3β amino acid (AA) sequence of patient 1 was detected in two other patients. CDR3β loops with closely related AA sequences were only found in patient 1. There were no CDR3β AA sequences with side chains of identical chemical properties detected in any patient.

Conclusion

We provide the first data addressing TCR Vβ chain usage in WT1-specific T-cell populations after HLA A*0201-restricted single peptide vaccination. We demonstrate both shared Vβ restriction and the sharing of a TCR β transcript with proven clinical impact in one patient.

Nur mit Berechtigung zugänglich

Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ (2008) Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111(1):236–242. doi:10.1182/blood-2007-08-108241 PubMedCrossRef

Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C (2009) A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113(26):6541–6548. doi:10.1182/blood-2009-02-202598 PubMedCrossRef

Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, Elisseeva OA, Masuda T, Nakano A, Kawakami M, Oji Y, Ikegame K, Hosen N, Udaka K, Yasukawa M, Ogawa H, Kawase I, Sugiyama H (2003) Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 78(1):56–61PubMedCrossRef

Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U (2002) CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100(6):2132–2137. doi:10.1182/blood-2002-01-0163 PubMedCrossRef

Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD (2006) In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 310(1–2):40–52. doi:10.1016/j.jim.2005.11.023 PubMedCrossRef

Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD (2007) Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110(1):201–210. doi:10.1182/blood-2006-11-056168 PubMedCrossRef

Argaet VP, Schmidt CW, Burrows SR, Silins SL, Kurilla MG, Doolan DL, Suhrbier A, Moss DJ, Kieff E, Sculley TB, Misko IS (1994) Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med 180(6):2335–2340PubMedCrossRef

Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schroder R, Deckert M, Schmidt S, Ravid R, Rajewsky K (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192(3):393–404PubMedCrossRef

Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, Adelsberger JW, Borrow P, Saag MS, Shaw GM, Sekaly RP et al (1994) Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370(6489):463–467. doi:10.1038/370463a0 PubMedCrossRef

10.

Moss PA, Moots RJ, Rosenberg WM, Rowland-Jones SJ, Bodmer HC, McMichael AJ, Bell JI (1991) Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. Proc Natl Acad Sci USA 88(20):8987–8990PubMedCrossRef

11.

Lehner PJ, Wang EC, Moss PA, Williams S, Platt K, Friedman SM, Bell JI, Borysiewicz LK (1995) Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. J Exp Med 181(1):79–91PubMedCrossRef

12.

Callan MF, Annels N, Steven N, Tan L, Wilson J, McMichael AJ, Rickinson AB (1998) T cell selection during the evolution of CD8+ T cell memory in vivo. Eur J Immunol 28(12):4382–4390. doi:10.1002/(SICI)1521-4141(199812)28:12<4382:AID-IMMU4382>3.0.CO;2-Z PubMedCrossRef

13.

Hong J, Zang YC, Tejada-Simon MV, Kozovska M, Li S, Singh RA, Yang D, Rivera VM, Killian JK, Zhang JZ (1999) A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol 163(6):3530–3538. doi:ji_v163n6p3530

14.

Burrows SR, Silins SL, Moss DJ, Khanna R, Misko IS, Argaet VP (1995) T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med 182(6):1703–1715PubMedCrossRef

15.

Lim A, Trautmann L, Peyrat MA, Couedel C, Davodeau F, Romagne F, Kourilsky P, Bonneville M (2000) Frequent contribution of T cell clonotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: application to direct detection of their molecular imprint on the human peripheral T cell repertoire. J Immunol 165(4):2001–2011. doi:ji_v165n4p2001 PubMed

16.

Kuwana M, Medsger TA Jr, Wright TM (1997) Highly restricted TCR-alpha beta usage by autoreactive human T cell clones specific for DNA topoisomerase I: recognition of an immunodominant epitope. J Immunol 158(1):485–491PubMed

17.

Tynan FE, Burrows SR, Buckle AM, Clements CS, Borg NA, Miles JJ, Beddoe T, Whisstock JC, Wilce MC, Silins SL, Burrows JM, Kjer-Nielsen L, Kostenko L, Purcell AW, McCluskey J, Rossjohn J (2005) T cell receptor recognition of a ‘super-bulged’ major histocompatibility complex class I-bound peptide. Nat Immunol 6(11):1114–1122. doi:10.1038/ni1257 PubMedCrossRef

18.

Kjer-Nielsen L, Clements CS, Brooks AG, Purcell AW, Fontes MR, McCluskey J, Rossjohn J (2002) The structure of HLA-B8 complexed to an immunodominant viral determinant: peptide-induced conformational changes and a mode of MHC class I dimerization. J Immunol 169(9):5153–5160PubMed

19.

Turner SJ, Kedzierska K, Komodromou H, La Gruta NL, Dunstone MA, Webb AI, Webby R, Walden H, Xie W, McCluskey J, Purcell AW, Rossjohn J, Doherty PC (2005) Lack of prominent peptide-major histocompatibility complex features limits repertoire diversity in virus-specific CD8+ T cell populations. Nat Immunol 6(4):382–389. doi:10.1038/ni1175 PubMedCrossRef

20.

Kedzierska K, Day EB, Pi J, Heard SB, Doherty PC, Turner SJ, Perlman S (2006) Quantification of repertoire diversity of influenza-specific epitopes with predominant public or private TCR usage. J Immunol 177(10):6705–6712. doi:177/10/6705 PubMed

21.

Kedl RM, Rees WA, Hildeman DA, Schaefer B, Mitchell T, Kappler J, Marrack P (2000) T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 192(8):1105–1113PubMedCrossRef

22.

Turner SJ, Doherty PC, McCluskey J, Rossjohn J (2006) Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol 6(12):883–894. doi:10.1038/nri1977 PubMedCrossRef

23.

Cole DJ, Wilson MC, Rivoltini L, Custer M, Nishimura MI (1997) T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Cancer Res 57(23):5320–5327PubMed

24.

Dietrich PY, Walker PR, Quiquerez AL, Perrin G, Dutoit V, Lienard D, Guillaume P, Cerottini JC, Romero P, Valmori D (2001) Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res 61(5):2047–2054PubMed

25.

Pittet MJ, Gati A, Le Gal FA, Bioley G, Guillaume P, de Smedt M, Plum J, Speiser DE, Cerottini JC, Dietrich PY, Romero P, Zippelius A (2006) Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J Immunol 176(4):2330–2336. doi:176/4/2330 PubMed

26.

Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wolfel T et al (1995) Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA 92(12):5674–5678PubMedCrossRef

27.

Trautmann L, Labarriere N, Jotereau F, Karanikas V, Gervois N, Connerotte T, Coulie P, Bonneville M (2002) Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol 32(11):3181–3190. doi:10.1002/1521-4141(200211)32:11<3181:AID-IMMU3181>3.0.CO;2-2 PubMedCrossRef

28.

Derre L, Bruyninx M, Baumgaertner P, Ferber M, Schmid D, Leimgruber A, Zoete V, Romero P, Michielin O, Speiser DE, Rufer N (2008) Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157–165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci USA 105(39):15010–15015. doi:10.1073/pnas.0807954105 PubMedCrossRef

29.

Ochsenreither S, Fusi A, Busse A, Bauer S, Scheibenbogen C, Stather D, Thiel E, Keilholz U, Letsch A (2011) “Wilms Tumor Protein 1” (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J Immunother 34(1):85–91. doi:10.1097/CJI.0b013e3181f3cc5c PubMedCrossRef

30.

Giudicelli V, Chaume D, Lefranc MP (2005) IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res 33 (Database issue):D256–D261. doi:10.1093/nar/gki010

31.

Ochsenreither S, Fusi A, Busse A, Letsch A, Haase D, Thiel E, Scheibenbogen C, Keilholz U (2009) Long term presence of a single predominant tyrosinase-specific T-cell clone associated with disease control in a patient with metastatic melanoma. Int J Cancer. doi:10.1002/ijc.24939

32.

Keilholz U, Golding-Lang P, Bechrakis NE, Max N, Letsch A, Schmittel A, Scheibenbogen C, Heufelder K, Egermont A, Thiel E (2004) Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 10:1605–1612PubMedCrossRef

33.

Ochsenreither S, Fusi A, Busse A, Nagorsen D, Schrama D, Becker J, Thiel E, Keilholz U (2008) Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations. J Transl Med 6:34. doi:10.1186/1479-5876-6-34 PubMedCrossRef

34.

Brochet X, Lefranc MP, Giudicelli V (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36 (Web Server issue):W503–W508. doi:10.1093/nar/gkn316

35.

Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4(4):406–425PubMed

36.

Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, Wu Y, Gemrot E, Brochet X, Lane J, Regnier L, Ehrenmann F, Lefranc G, Duroux P (2009) IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 37 (Database issue):D1006–D1012. doi:10.1093/nar/gkn838

37.

Trautmann L, Rimbert M, Echasserieau K, Saulquin X, Neveu B, Dechanet J, Cerundolo V, Bonneville M (2005) Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J Immunol 175(9):6123–6132. doi:175/9/6123 PubMed

38.

Vignard V, Lemercier B, Lim A, Pandolfino MC, Guilloux Y, Khammari A, Rabu C, Echasserieau K, Lang F, Gougeon ML, Dreno B, Jotereau F, Labarriere N (2005) Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol 175(7):4797–4805. doi:175/7/4797 PubMed

39.

Yokosuka T, Takase K, Suzuki M, Nakagawa Y, Taki S, Takahashi H, Fujisawa T, Arase H, Saito T (2002) Predominant role of T cell receptor (TCR)-alpha chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system. J Exp Med 195(8):991–1001PubMedCrossRef

40.

Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P (1999) A direct estimate of the human alphabeta T cell receptor diversity. Science 286(5441):958–961. doi:7939 PubMedCrossRef

41.

Campregher PV, Srivastava SK, Deeg HJ, Robins HS, Warren EH (2010) Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome. Exp Hematol 38(3):202–212. doi:10.1016/j.exphem.2009.12.004 PubMedCrossRef

42.

Sloand EM, Melenhorst JJ, Tucker ZC, Pfannes L, Brenchley JM, Yong A, Visconte V, Wu C, Gostick E, Scheinberg P, Olnes MJ, Douek DC, Price DA, Barrett AJ, Young NS (2011) T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 117(9):2691–2699. doi:10.1182/blood-2010-04-277921 PubMedCrossRef

43.

Serana F, Sottini A, Caimi L, Palermo B, Natali PG, Nistico P, Imberti L (2009) Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients. J Transl Med 7:21. doi:10.1186/1479-5876-7-21 PubMedCrossRef

44.

Venturi V, Price DA, Douek DC, Davenport MP (2008) The molecular basis for public T-cell responses? Nat Rev Immunol 8(3):231–238. doi:10.1038/nri2260 PubMedCrossRef

45.

Venturi V, Kedzierska K, Price DA, Doherty PC, Douek DC, Turner SJ, Davenport MP (2006) Sharing of T cell receptors in antigen-specific responses is driven by convergent recombination. Proc Natl Acad Sci USA 103(49):18691–18696. doi:10.1073/pnas.0608907103 PubMedCrossRef

46.

Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, Riddell SR, Warren EH, Carlson CS (2009) Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114(19):4099–4107. doi:10.1182/blood-2009-04-217604 PubMedCrossRef

47.

Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, Shih G, Zhang M, Coccia MA, Kohno T, Tafuri-Bladt A, Brankow D, Campbell P, Chang D, Chiu L, Dai T, Duncan G, Elliott GS, Hui A, McCabe SM, Scully S, Shahinian A, Shaklee CL, Van G, Mak TW, Senaldi G (1999) T-cell co-stimulation through B7RP-1 and ICOS. Nature 402(6763):827–832. doi:10.1038/45582 PubMedCrossRef

48.

de Souza AP, Bonorino C (2009) Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 9(9):1317–1332. doi:10.1586/era.09.88 PubMedCrossRef

49.

Gaur U, Aggarwal BB (2003) Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66(8):1403–1408. doi:S0006295203004908 PubMedCrossRef

Titel: Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients
verfasst von: Sebastian Ochsenreither
Alberto Fusi
Anne Geikowski
David Stather
Antonia Busse
Andrea Stroux
Anne Letsch
Ulrich Keilholz
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 3/2012
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1099-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients

Abstract

Background

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer

HP-NAP new therapy for bladder cancer: numquam periculum sine periculo vincitur

Response to the rebuttal letter of Kountouras and colleagues regarding the paper by Codolo et al. ‘HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response’

Design of immunogenic and effective multi-epitope DNA vaccines for melanoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie